Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...
The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...
Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback